首页> 美国卫生研究院文献>Oncotarget >Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer
【2h】

Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer

机译:基于尿细胞microRNA的非肌肉浸润性膀胱癌预后分类器

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Current prognostic tools for non-muscle invasive bladder cancer (NMIBC) do not have enough discriminative capacity to predict the risk of tumour progression. This study aimed to identify urinary cell microRNAs that may be useful as non-invasive predictive biomarkers of tumour progression in NMIBC patients. To this end, 210 urine samples from NMIBC patients were included in the study. RNA was extracted from urinary cells and expression of 8 microRNAs, previously described by our group, was analysed by quantitative PCR. A tumour progression predicting model was developed by Cox regression analysis and validated by bootstrapping. Regression analysis identified miR-140-5p and miR-92a-3p as independent predictors of tumour progression. The risk score derived from the model containing these two microRNAs was able to discriminate between two groups with a highly significant different probability of tumour progression (HR, 5.204; p<0.001) which was maintained when patients were stratified according to tumour risk. The algorithm was also able to identify two groups with different cancer-specific survival (HR, 3.879; p=0.021). Although the data needs to be externally validated, miRNA analysis in urine appears to be a valuable prognostic tool in NMIBC patients.
机译:当前用于非肌肉浸润性膀胱癌(NMIBC)的预后工具尚无足够的判别能力来预测肿瘤进展的风险。这项研究旨在鉴定尿细胞微RNA,这些微RNA可用作NMIBC患者肿瘤进展的非侵入性预测生物标志物。为此,研究中包括了NMIBC患者的210个尿液样本。从泌尿细胞中提取RNA,并通过定量PCR分析了我们小组先前描述的8个microRNA的表达。通过Cox回归分析开发了肿瘤进展预测模型,并通过自举验证了模型。回归分析确定miR-140-5p和miR-92a-3p是肿瘤进展的独立预测因子。从包含这两种microRNA的模型得出的风险评分能够区分两组,肿瘤进展的可能性极高(HR,5.204; p <0.001),当根据患者的肿瘤风险对患者进行分层时,这些风险得以维持。该算法还能够识别出具有不同癌症特异性生存率的两组(HR,3.879; p = 0.021)。尽管数据需要外部验证,但尿液中的miRNA分析似乎是NMIBC患者的宝贵预后工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号